LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04390217 |
Recruitment Status :
Withdrawn
(Company focused on other clinical programs)
First Posted : May 15, 2020
Last Update Posted : May 13, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COVID-19 Coronavirus Disease 2019 Covid19 COVID-19 Pneumonia | Drug: LB1148 Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | All patients will be randomized into one of two treatment groups (LB1148 or Placebo) in a 1:1 ratio, and stratified by peripheral capillary oxygen saturation and by PF ratio at the time of Screening. |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | Quadruple blinding including the sponsor and all sponsor agents, subjects, investigators, care providers, and family members. |
Primary Purpose: | Treatment |
Official Title: | A Phase 2 Study to Evaluate LB1148 for the Treatment of Pulmonary Dysfunction Associated With COVID-19 Pneumonia |
Estimated Study Start Date : | October 31, 2021 |
Estimated Primary Completion Date : | December 31, 2021 |
Estimated Study Completion Date : | March 31, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: LB1148
LB1148 contains 7.5 g TXA, polyethylene glycol (PEG), glucose, and electrolytes. A total of 700 mL of LB1148 Active will be administered daily as a split dose (350 mL, every 12 hours) for up to 7 days. LB1148 Active is given as a single bolus, to be delivered orally or enterally via NG/OG tube, and should be fully consumed or delivered within 2 hours of the start of administration.
|
Drug: LB1148
LB1148 is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
Other Name: tranexamic acid (TXA) |
Placebo Comparator: Placebo
Placebo contains polyethylene glycol (PEG), glucose, and electrolytes. A total of 700 mL of LB1148 Placebo will be administered daily as a split dose (350 mL, every 12 hours) for up to 7 days. LB1148 Placebo is given as a single bolus, to be delivered orally or enterally via NG/OG tube, and should be fully consumed or delivered within 2 hours of the start of administration.
|
Drug: Placebo
Placebo is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days. |
- Effect of LB1148 on disease progression via measurement of the proportion of patients who are alive and free of respiratory failure. [ Time Frame: 28 Days ]The proportion of subjects alive and free of respiratory failure at Day 28.
- Clinical status at fixed time points [ Time Frame: Measured at 3, 5, 7, 8, 10, 14 and 28 Days ]Number and proportion of patients with improved clinical status as assessed by a 9-point ordinal scale of disease severity at fixed timepoints (Days 3, 5, 7, 8, 10, 14, 28)
- Duration of hospital stay [ Time Frame: 28 Days ]Length of hospital stay (live discharge)
- Measurement of the number and proportion of patients requiring admission to the intensive care unit (ICU) during hospitalization [ Time Frame: 28 Days ]Number and proportion of patients requiring admission to the intensive care unit
- Duration of ICU stay [ Time Frame: 28 Days ]Length of ICU stay
- Invasive mechanical ventilation requirements [ Time Frame: 28 Days ]Number and proportion of patients requiring invasive mechanical ventilation
- Duration of invasive mechanical ventilation [ Time Frame: 28 Days ]Length of time patients require invasive mechanical ventilation
- All-cause 28-day mortality [ Time Frame: 28 Days ]The number and proportion of patients deceased at Day 28
- Safety and tolerability of LB1148 [ Time Frame: 28 Days ]The incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adult patients (18 years of age or older) with the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, confirmed via an established standard reverse transcriptase polymerase chain reaction (RT-PCR) assay.
- Patient or patient's legally authorized representative is willing and able to provide informed consent prior to performing any study-related procedures.
- Patient is hospitalized and requires some form of supplemental oxygen, e.g., non-invasive ventilation, high flow oxygen device, or oxygen by mask or nasal cannula.
- Patient has radiographic evidence of pulmonary infiltrate(s) or lung inflammation.
Exclusion Criteria:
- Participation in any other interventional clinical trial using an experimental treatment (drug or device) for COVID-19.
- Expected survival or time to withdrawal of life-sustaining treatments is expected to be < 7 days.
- Patients with do not intubate orders.
- Patients who require invasive mechanical ventilation at the time of Screening.
- Patients who require renal replacement therapy (RRT) at the time of Screening.
- Patients with known aspiration problems.
-
Has contraindications or potential risk factors to taking TXA. These include patients with:
- Known sensitivity to TXA;
- Recent craniotomy (past 30 days);
- Active cerebrovascular bleed;
- Active thromboembolic disease (such as deep vein thrombosis, pulmonary embolism, cerebral thrombosis, ischemic stroke, or acute coronary syndrome);
- Acute promyelocytic leukemia taking all-trans retinoic acid for remission induction
- Continuing use of a combined hormonal contraceptive and or combined hormonal replacement therapy (including combined hormonal pill, patch, or vaginal ring).
- Concomitant therapy with tissue plasminogen activators, Factor IX complex concentrates or anti-inhibitor coagulant concentrates.
-
Known medical history of congenital or acquired thrombophilia such as, but not limited to patients with:
- Sickle cell disease
- Nephrotic syndrome
- Factor V Leiden
- Prothrombin gene mutation
- Protein C or S deficiency
- Antithrombin III deficiency
- Antiphospholipid syndrome
- Patients with myeloproliferative disorders.
- Any other condition that, in the opinion of the treating Investigator, would preclude the patient from being an appropriate candidate for the study.
- Female patients who are pregnant or breastfeeding at the time of Screening.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04390217
Study Director: | Michael J Dawson, MD | Leading BioSciences, Inc |
Responsible Party: | Leading BioSciences, Inc |
ClinicalTrials.gov Identifier: | NCT04390217 |
Other Study ID Numbers: |
LBS-COVID19-201 |
First Posted: | May 15, 2020 Key Record Dates |
Last Update Posted: | May 13, 2022 |
Last Verified: | May 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 Pneumonia Respiratory Tract Infections Infections Pneumonia, Viral Virus Diseases Coronavirus Infections Coronaviridae Infections Nidovirales Infections |
RNA Virus Infections Lung Diseases Respiratory Tract Diseases Tranexamic Acid Antifibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Hemostatics Coagulants |